Contact us

Our latest news

Back to news >

Seda announces £4m investment in new state-of-the-art facilities

With huge growth in demand for its services, Greater Manchester-based Seda Pharmaceutical Development Services (Seda) has acquired a new property and is on track to double its annual turnover to at least £7m in the next two years.

Explore Seda’s new home using the interactive Google Street View map above. More images to follow as the refurbishment progresses.

Seda provides pharmaceutical development and clinical pharmacology services to the pharmaceutical and biotechnology industries. These include:

  • CMC and Clinical Pharmacology Consultancy
  • PK and PBPK Modelling
    • Translational PK-PD modelling
    • Dose selection and dose justification
    • Population PK and Noncompartmental Analysis
  • Laboratory Services
    • Enabled Preclinical Formulations
    • Early and Late Phase Clinical Formulations and Processes
    • Biorelevant and  clinically relevant dissolution (CRDS) testing
    • Standard and Complex parenteral products (e.g. delivery of new modalities such as mRNA)

With rapidly increasing demand for its services, it has outgrown its current rental facility in Macclesfield.

Santander UK, which Seda has banked with since its inception in 2015, has provided it with a funding package of £2m which includes support for the acquisition of its new property in Cheadle, Stockport.

Seda will undertake a full refit of the new property, with total investment nearing £4m, developing state-of-the-art laboratories and bespoke office space. This will enable it to invest in new equipment so it can expand the range of services it offers clients. Among the new facilities and equipment in plan are processing suites for oral solid dosage forms (tablets and capsules) and enhanced facilities for parenteral products (injections). A particular area of focus is building capabilities in nano formulation prototyping and characterisation for the design and development of complex medicines such as lipid nanoparticles for mRNA delivery (as used in some Covid vaccines). These additions are crucial for Seda to fulfil rapidly growing demand from clients worldwide.

Seda, which recently won Best Contract Research Organisation (CRO) in the 2021 OBN Awards, currently has a permanent staff of 23 and a network of expert associate subcontractors. It is working toward growing its permanent staff to at least 50 by April 2024, initially by recruiting analysts, formulators, modellers, project managers, and later, non-technical support staff.

Seda CEOPaul Stott, CEO of Seda said: “The purchase of our own facility allows us to make long term capital investments in the capabilities that our clients need – something that was not economically viable with our current rental property. It will also give us a superb working environment for our expanding team.
Through the support of Santander UK, we have been able to do this without taking any dilutive funding. Our continued independence enables us to maintain control of all decisions, future direction and to maintain the highest scientific standards.”


Debbie Worthington, Relationship Director at Santander UK, said: “Santander UK is well equipped to provide specialist support to companies in the pharmaceutical and medical sectors and we’re delighted to see a company in this industry, that has banked with us since inception, grow so rapidly and have such an exciting future ahead. Seda is making a significant and positive contribution to medical science internationally and as its banking partner, we are pleased to be able to support its ongoing expansion and success.”

Read the full press release here: Healthy dose of support from Santander UK for pharmaceutical development services firm | Santander UK